Scarica l'app Stockscreener
1,094.58
9.24%
91.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1,003.46
Aprire:
$1075.12
Volume 24 ore:
5.10M
Relative Volume:
1.43
Capitalizzazione di mercato:
$979.39B
Reddito:
$59.42B
Utile/perdita netta:
$18.41B
Rapporto P/E:
54.13
EPS:
20.2197
Flusso di cassa netto:
$6.44B
1 W Prestazione:
+7.07%
1M Prestazione:
+1.46%
6M Prestazione:
+42.54%
1 anno Prestazione:
+32.70%
Intervallo 1D:
$1,065.00
$1,111.08
Intervallo di 1 settimana:
$993.58
$1,111.08
Portata 52W:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,094.27 | 898.12B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
235.28 | 561.61B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
219.90 | 398.83B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
119.48 | 287.52B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
NVS
Novartis Ag Adr
|
154.05 | 287.55B | 54.45B | 14.42B | 17.15B | 7.333 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Lilly runs up stock market on better estimates than Novo Nordisk for anti-obesity drugs - Il Sole 24 ORE
Eli Lilly stock rises as Deutsche Bank reiterates Buy rating on strong 2026 guidance - Investing.com
Research Alert: CFRA Raises Rating On Shares Of Eli Lilly And Company To Strong Buy From Buy - 富途牛牛
Eli Lilly Investing $3.5 Billion in Pennsylvania Site - AdvancedManufacturing.org
Eli Lilly Shows Why the GLP-1 Trade Is Still About Volume, Not Pricing - Investing.com
Novo Nordisk’s shares tumble after sales warning as gap widens with Eli Lilly - Financial Times
Eli Lilly (LLY) Stock Trades Up, Here Is Why - Finviz
Mounjaro maker Eli Lilly flattens Wegovy rival Novo Nordisk in battle of the fat jabs - This is Money
Earnings call transcript: Eli Lilly’s Q4 2025 results beat expectations By Investing.com - Investing.com South Africa
Eli Lilly Q4 2025 Earnings Call Transcript - Benzinga
Top Midday Stories: Lilly Shares Soar After Strong Q4 Earnings, Guidance; Uber Q4 EPS Misses Target, CFO Stepping Down - 富途牛牛
Eli Lilly (LLY) Q4 2025 Earnings Call Transcript - AOL.com
Eli Lilly Q4 2025 slides: Revenue soars 43% as obesity treatments dominate market - Investing.com
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 - The Motley Fool
Lilly earnings continue upward path on growth of Zepbound, Mounjaro - Inside INdiana Business
Q4 Earnings Summary: Eli Lilly and AbbVie Beat, Uber Mixed - Investing.com
Goldman Sachs Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,145 - 富途牛牛
Forecast-topping Lilly leaves Novo Nordisk in the shade - The Pharma Letter
AMD, Eli Lilly among market cap stock movers on Wednesday - Investing.com
AMD, Eli Lilly among market cap stock movers on Wednesday By Investing.com - Investing.com UK
Eli Lilly (LLY) Surges on Strong Earnings Beat and Positive Outl - GuruFocus
Dow edges up as Lilly, Super Micro earnings cushion software jitters - MSN
Eli Lilly stock outperforms as Leerink reiterates rating on strong 2026 guidance - Investing.com
LLY stock jumps 9%: Why Eli Lilly stock is soaring todayMounjaro, Zepbound sales drive massive earnings beat and 2026 forecast stuns Wall Street - The Economic Times
Lilly Sees Surging Sales in Contrast to Obesity Rival Novo - Bloomberg.com
Global 'blockbuster drug' throne shifts! Eli Lilly and Co's tirzepatide takes the crown. - 富途牛牛
Mounjaro Maker Eli Lilly Banks On Bigger 2026 Thanks To Weight Loss DrugsEli Lilly and Co (NYSE:LLY) - Benzinga
Truist Securities reiterates buy rating on Eli Lilly stock after strong earnings - Investing.com
Key highlights from Eli Lilly’s (LLY) Q4 2025 earnings results - AlphaStreet
Eli Lilly beats estimates and forecasts strong 2026 as obesity drug demand surges - Business Day
Eli Lilly (LLY) Surges 7% After Beating Q4 Expectations and Stro - GuruFocus
Eli Lilly issues upbeat guidance for 2026 amid solid demand for weight-loss drugs - Sharecast News
Eli Lilly (LLY) Reports Strong Q4 Earnings, Surpassing Estimates - GuruFocus
Eli Lilly surges 7% after earnings driven by obesity drugs 📈 - XTB.com
Eli Lilly (NYSE:LLY) Reports Strong Q4 CY2025, Stock Soars - Finviz
Lilly beats earnings estimates, issues upbeat forecast on soaring weight‑loss drug demand - BNN Bloomberg
Eli Lilly (LLY) Surpasses Revenue Expectations in Q4 - GuruFocus
Eli Lilly & Co. (NYSE:LLY) Soars on Blockbuster Q4 Earnings and Upbeat 2026 Guidance - Chartmill
AMD, Uber, Chipotle and Novo Nordisk fell premarket; Alphabet, Eli Lilly rose By Investing.com - Investing.com South Africa
Eli Lilly crushes Q4 estimates, gives cheery 2026 guidance - Sherwood News
LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook - Stocktwits
Eli Lilly Reports Strong Q4 2025 Financial Results and Provides 2026 Guidance - TradingView
Eli Lilly (LLY) Q4 Earnings Exceed Expectations, Shares Rise - GuruFocus
Eli Lilly And Co. Profit Advances In Q4 - Nasdaq
Lilly: Q4 Earnings Snapshot - marketscreener.com
Lilly sees strong growth in 2026 as weight-loss drug rival Novo slips - Reuters
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance - PR Newswire
Lilly soars again as fast-selling weight loss drugs top Wall Street projections - Yahoo Finance
Eli Lilly Stock Price (LLY) Holding On To $1000 Ahead of Earnings – What Next? - AskTraders.com
Eli Lilly shares soar after Q4 beat, strong forecast on weight-loss drugs - Proactive financial news
Ashton Thomas Private Wealth LLC Has $16.21 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.88%
3.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):